Lapovis Plus (Latanoprost, Timolol)

• Lapovis Plus combines a prostaglandin analog and a beta‑blocker to lower intra‑ocular pressure in glaucoma‑related conditions.
• Open‑angle glaucoma: provides a dual mechanism that reduces aqueous humor production and enhances outflow, achieving a sustained decrease in intra‑ocular pressure and helping to preserve visual field.
• Ocular hypertension: lowers elevated eye pressure in patients without optic nerve damage, reducing the risk of developing glaucoma over time.
• Secondary open-angle glaucoma: offers effective pressure control in cases where other therapies are insufficient, supporting optic nerve health alongside standard treatments.

• Latanoprost is a prostaglandin F2α analogue that binds to FP receptors in the ciliary body, increasing uveoscleral outflow of aqueous humor. Timolol is a non‑selective β‑adrenergic antagonist that blocks β1 and β2 receptors in the ciliary epithelium, decreasing aqueous humor production. This dual mechanism provides a more consistent pressure‑lowering effect compared with monotherapy.

Eye drops containing latanoprost and timolol may be associated with ocular and systemic adverse reactions.

Common Side Effects

• Eye redness: transient hyperemia of the conjunctiva.
• Eye irritation or foreign‑body sensation.
• Blurred vision: temporary reduction in visual clarity.
• Increased eyelash growth or darkening of the iris.
• Dry eye: decreased tear production.
• Mild eye discharge: occasional tearing or watery eyes.

Serious or Rare Side Effects

• Severe allergic reaction: swelling, rash, or anaphylaxis.
• Acute angle‑closure glaucoma: sudden eye pain and vision loss.
• Systemic bradycardia or hypotension: especially in patients with cardiac disease.

When prescribing Lapovis Plus, clinicians should consider several precautionary measures to ensure patient safety.

• Assess cardiovascular status: avoid use in patients with severe bradycardia or heart block.
• Review respiratory history: contraindicated in patients with asthma or chronic obstructive pulmonary disease.
• Monitor intra‑ocular pressure: check pressure response after initiation and adjust therapy as needed.
• Avoid contact lens wear: discontinue lenses for at least 15 minutes after instillation.
• Discontinue if allergic reaction occurs: stop treatment and seek medical attention.
• Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost/timolol eye drops can interact with other ophthalmic or systemic agents.

Major Interactions (Avoid)

• Systemic non‑selective β‑blockers (e.g., propranolol): may cause additive bradycardia or hypotension.
• Other prostaglandin analogues: concurrent use can increase risk of ocular hyperemia and iris pigmentation.
• Sympathomimetic eye drops (e.g., phenylephrine): may reduce the intra‑ocular pressure‑lowering effect.

Moderate Interactions (Monitor Closely)

• Carbonic anhydrase inhibitors (e.g., dorzolamide): additive pressure‑lowering effect may require dose adjustment.
• Anticholinergic eye drops: may affect pupil size and comfort.